- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Telling it how it is: The need for plain language summaries in medical journals | ||
| Do | Life-science logistics specialist opens Los Angeles location | ||
| Do | FDA authorizes Pfizer-BioNTech COVID-19 booster shot for high risk individuals | ||
| Do | Ocular gene therapy biotech launches with $19M seed funding | ||
| Do | AstraZeneca invests in saRNA specialist | ||
| Do | AstraZeneca invests in saRNA specialist, VaxEquity, an Imperial College spin-off | ||
| Di | Boehringer Ingelheim acquires Abexxa Biologics | ||
| Di | Novartis acquires Arctos Medical to expand optogenetics portfolio | ||
| Di | Naobios and FluGen alliance continues: Production of intranasal flu vaccine clinical batches to get underway | ||
| Di | Samsung, Biogen get US green light for biosimilar to blockbuster Roche drug | ||
| 20.09. | Pfizer & BioNTech COVID-19 vaccine is 'safe, well-tolerated and shows robust neutralizing antibody responses' in children | ||
| 20.09. | Touchlight extends funding round, sees hike in demand for synthetic DNA vectors | ||
| 20.09. | Self-amplifying mRNA COVID-19 vaccine 'immunogenicity enhancer' enters Phase 1 trial | ||
| 20.09. | Intravacc looks to contract research, intranasal and cancer vaccine pipeline as revenue drivers | ||
| 16.09. | Pfizer's mRNA flu vaccine candidate set to enter clinic | ||
| 16.09. | AGC Biologics invests in Germany to address booming mRNA industry | ||
| 15.09. | APAC region: Cytiva and Wego in capacity expansion move to support single-use technology trend | ||
| 14.09. | Encouraging data from Johnson & Johnson on Ebola vaccine | ||
| 14.09. | BMS joins $75m funding round for French biotech developing pipeline of stem cell-derived cell therapies | ||
| 14.09. | CureVac terminates COVID-19 vaccine manufacturing contracts with Wacker and Celonic | ||
| 13.09. | 3i invests in new Switzerland based biologics-focused CDMO | ||
| 13.09. | UK rips up COVID-19 vaccine contract with Valneva | ||
| 13.09. | AbbVie, Regenxbio in macular degeneration focused gene therapy deal | ||
| 09.09. | Thermo Fisher Scientific to double SUT manufacturing capacity with new Nashville site | ||
| 09.09. | Roche's Genentech inks $3bn+ pact with Adaptimmune to make cell therapies 'curative and mainstream' |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
